SECONDARY ACUTE MYELOID LEUKEMIA

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The goal …

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) helps older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer returning. About 60 participants who are not e…

This study tests a chemotherapy drug called CPX-351 in people under 60 who have a type of leukemia that developed from a previous blood disorder or cancer treatment. The goal is to see how well the drug can stop the cancer from growing and achieve remission. About 21 participants…

This early-phase study tests a combination of two drugs—ipilimumab (an immunotherapy that helps the immune system attack cancer) and decitabine (a chemotherapy drug)—in adults with myelodysplastic syndrome or acute myeloid leukemia that has returned or not responded to prior trea…

This early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for people with acute myeloid leukemia (AML). It includes older adults who cannot have standard treatment or those with relapsed or hard-to-treat AML. The goal is to find a to…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see if the combination could safely lead to complete remission (no signs of cancer) and improve surviv…

This early-stage study tests a new way to prepare the body for a donor stem cell transplant in people with high-risk leukemia or myelodysplastic syndrome (MDS). It combines targeted radiation (TMLI) with two chemotherapy drugs to kill cancer cells and make room for healthy donor …

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with two standard drugs, decitabine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find the safest dose and understand…

This study tests whether adding the drug decitabine to standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with less favorable types of AML will receive either low or high dose decitabine alongside chemo. The goal is to…

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. The drug works by targeting a protein on cancer cells to stop …

This early-phase study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells that are genetically modified to recognize and attack cancer cells ca…

This study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. About 48 patients will take part in up to 7 counseling sessions to learn new ways to cope with fatigue. The g…